Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: Analysis of  Surgery-related Risks

Oya, Soichi; Ikawa, Fusao; Ichihara, Nao; Wanibuchi, Masahiko; Akiyama, Yukinori; Nakatomi, Hirofumi; Mikuni, Nobuhiro; Narita, Yoshitaka

doi:10.2176/nmc.oa.2020-0304

Cited by 11 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study showed a rate of overall major AE of 20.6% and a rate of 12.8% for onset of new focal neurological deficit, which are both in line with recently published studies in the literature [4,22].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Preoperative risk factors associated with new focal neurological deficit and other major adverse events in first-time intracranial meningioma neurosurgery

et al. 2021

View full text Add to dashboard Cite

Background Neurosurgical resection is the mainstay of meningioma treatment. Adverse event (AE) rates of meningioma resections are significant, but preoperative risk factors for major AEs in patients undergoing first-time meningioma surgery are largely unknown. The aim of this study was to explore major AEs and identify preoperative risk factors in patients undergoing first-time meningioma surgery. Methods Data on all meningioma resections performed at the University Hospital Zurich from 1 January 2013 to 31 December 2018 were collected in a prospective registry. All AEs that occurred within 3 months of surgery were documented in detail and classified as “minor” or “major.” Statistical analysis included initial individual bivariate analyses of all preoperative factors and the occurrence of major AEs. Statistically significant variables were then included in a logistic regression model to identify predictors. Results Three hundred forty-five patients were included in the study. Mean age was 58.1 years, and 77.1% of patients were female. The overall major AE rate was 20.6%; the most common of which was a new focal neurological deficit (12.8% of patients). Six preoperative factors showed a significant association with the occurrence of major AEs in bivariate analysis. All variables included in the logistic regression model showed increased odds of occurrence of major AE, but only tumor complexity as measured by the Milan Complexity Scale was a statistically significant predictor, with a score of 4 or more having twice the odds of major AEs (OR: 2.00, 95% CI: 1.15–3.48). Conclusion High tumor complexity is an independent predictor of the occurrence of major AEs following meningioma resection. Preoperative assessment of tumor complexity using the Milan Complexity Scale is warranted and can aid communication with patients about AE rates and surgical decision-making.

show abstract

Section: Discussionsupporting

confidence: 91%

“…Major AEs are common following meningioma surgery [ 4 , 22 ]. Many studies to-date have identified risk factors [ 3 , 7 , 11 , 16 , 17 , 20 , 24 , 31 ], but to our knowledge, none have looked specifically at major AE rates in first-time meningioma surgeries, including new focal neurological deficits as major AEs.…”

Section: Discussionmentioning

confidence: 99%

Preoperative risk factors associated with new focal neurological deficit and other major adverse events in first-time intracranial meningioma neurosurgery

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The JND was originally designed to have a multi-layered database, and the statistics of the first-layer database, covering all fields of subspecialties, is described in this paper. 1) Relevant societies of the subspecialties of the JNS published the paper using clinical registries such as the Japanese Registry of Neuroendovascular Therapy, 19 , 20 , 24) the Brain Tumor Registry of Japan, 25 , 26) the Japan Neurotrauma Data Bank, 6 , 27) and registries of pediatric neurosurgery, 28 , 29) functional neurosurgery, 30 , 31) unruptured aneurysms and cerebrovascular surgery, 32 , 33) moyamoya diseases, 34 – 36) and stereotactic radiosurgery.…”

Section: Discussionmentioning

confidence: 99%

The Japan Neurosurgical Database: Statistics Update 2018 and 2019

Iihara

Saito

Suzuki

et al. 2021

Neurol. Med. Chir.(Tokyo)

Self Cite

View full text Add to dashboard Cite

Each year, the Japan Neurosurgical Society (JNS) reports up-to-date statistics from the Japan Neurosurgical Database regarding case volume, patient demographics, and in-hospital outcomes of the overall cohort and neurosurgical subgroup according to the major classifications of main diagnosis. We hereby report patient demographics, in-hospital mortality, length of hospital stay, purpose of admission, number of medical management, direct surgery, endovascular treatment, and radiosurgery of the patients based on the major classifications and/or main diagnosis registered in 2018 and 2019 in the overall cohort (523283 and 571143 patients, respectively) and neurosurgical subgroup (177184 and 191595 patients, respectively). The patient demographics, disease severity, proportion of purpose of admission (e.g., operation, 33.9–33.5%) and emergent admission (68.4–67.8%), and in-hospital mortality (e.g., cerebrovascular diseases, 6.3–6.5%; brain tumor, 3.1–3%; and neurotrauma, 4.3%) in the overall cohort were comparable between 2018 and 2019. In total, 207783 and 225217 neurosurgical procedures were performed in the neurosurgical subgroup in 2018 and 2019, respectively, of which endovascular treatment comprised 19.1% and 20.3%, respectively. Neurosurgical management of chronic subdural hematoma (19.4–18.9%) and cerebral aneurysm (15.4–14.8%) was most common. Notably, the proportion of management of ischemic stroke/transient ischemic attack, including recombinant tissue plasminogen activator infusion and endovascular acute reperfusion therapy, increased from 7.5% in 2018 to 8.8% in 2019. The JNS statistical update represents a critical resource for the lay public, policy makers, media professionals, neurosurgeons, healthcare administrators, researchers, health advocates, and others seeking the best available data on neurosurgical practice.

show abstract

“…Supratentorial NSBM account for 40 to 60% of all intracranial meningiomas [ 4 , 6 , 7 , 8 , 9 ] ( Table 1 ). Meningioma incidence increases with age, with a median age at diagnosis of 66 years [ 1 ].…”

Section: Epidemiologymentioning

confidence: 99%

Clinical Management of Supratentorial Non-Skull Base Meningiomas

Adekanmbi

Youngblood

Karras

et al. 2022

Cancers

View full text Add to dashboard Cite

Supratentorial non-skull base meningiomas are the most common primary central nervous system tumor subtype. An understanding of their pathophysiology, imaging characteristics, and clinical management options will prove of substantial value to the multi-disciplinary team which may be involved in their care. Extensive review of the broad literature on the topic is conducted. Narrowing the scope to meningiomas located in the supratentorial non-skull base anatomic location highlights nuances specific to this tumor subtype. Advances in our understanding of the natural history of the disease and how findings from both molecular pathology and neuroimaging have impacted our understanding are discussed. Clinical management and the rationale underlying specific approaches including observation, surgery, radiation, and investigational systemic therapies is covered in detail. Future directions for probable advances in the near and intermediate term are reviewed.

show abstract

Nation-wide Brain Tumor Registry-based Study of Intracranial Meningioma in Japan: Analysis of Surgery-related Risks

Cited by 11 publications

References 28 publications

Preoperative risk factors associated with new focal neurological deficit and other major adverse events in first-time intracranial meningioma neurosurgery

Preoperative risk factors associated with new focal neurological deficit and other major adverse events in first-time intracranial meningioma neurosurgery

The Japan Neurosurgical Database: Statistics Update 2018 and 2019

Clinical Management of Supratentorial Non-Skull Base Meningiomas

Contact Info

Product

Resources

About